Bicara Therapeutics (BCAX) Stock Analysis

What Bicara Therapeutics does

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Key metrics

ETFs linked to BCAX

Broad-market and Healthcare sector ETFs an investor holding Bicara Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BCAX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Bicara Therapeutics?

Bicara Therapeutics trades under the ticker BCAX on NASDAQ.

Which exchange is BCAX listed on?

BCAX is listed on NASDAQ.

What sector does Bicara Therapeutics operate in?

Bicara Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BCAX in a portfolio?

PortView shows BCAX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.